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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease. For patients with localized PDAC, surgery
is the best option, but with a median survival of less than 2 years and a difficult and prolonged postoperative course for
most, there is an urgent need to better identify patients who have the most aggressive disease.
Methods and Findings: We analyzed the gene expression profiles of primary tumors from patients with localized compared
to metastatic disease and identified a six-gene signature associated with metastatic disease. We evaluated the prognostic
potential of this signature in a training set of 34 patients with localized and resected PDAC and selected a cut-point
associated with outcome using X-tile. We then applied this cut-point to an independent test set of 67 patients with localized
and resected PDAC and found that our signature was independently predictive of survival and superior to established
clinical prognostic factors such as grade, tumor size, and nodal status, with a hazard ratio of 4.1 (95% confidence interval [CI]
1.7–10.0). Patients defined to be high-risk patients by the six-gene signature had a 1-year survival rate of 55% compared to
91% in the low-risk group.
Conclusions: Our six-gene signature may be used to better stage PDAC patients and assist in the difficult treatment
decisions of surgery and to select patients whose tumor biology may benefit most from neoadjuvant therapy. The use of
this six-gene signature should be investigated in prospective patient cohorts, and if confirmed, in future PDAC clinical trials,
its potential as a biomarker should be investigated. Genes in this signature, or the pathways that they fall into, may
represent new therapeutic targets.
Please see later in the article for the Editors’ Summary.
Citation: Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, et al. (2010) A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic
Ductal Adenocarcinoma. PLoS Med 7(7): e1000307. doi:10.1371/journal.pmed.1000307
Academic Editor: Samir M. Hanash, Fred Hutchinson Cancer Research Center, United States of America
Received January 4, 2010; Accepted June 3, 2010; Published July 13, 2010
Copyright:  2010 Stratford et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Emerald Foundation (JJY), the Kimmel Foundation (JJY), the American College of Surgeons (JJY), the American Surgical
Association Foundation (JJY), the North Carolina University Cancer Research Fund (JJY), and the NCI SPORE in Gastrointestinal Cancer P50 CA106991 (jjy, cjd), NCI
SPORE in SPORE in Breast Cancer - Core 3 - Biostatistics 5-P50-CA58223-15 (JSM), NIH T32 Cancer Biology Training Grant (JKS), NIH CA106610 (CAI-D). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: DWD, distance weighted discrimination; NEB, University of Nebraska Medical Center Rapid Autopsy Pancreatic Program; PDAC, pancreatic ductal
adenocarcinoma; SAM, significance analysis of microarrays; TMA, tissue microarray; TNM, tumor, node, and metastasis; UNC, University of North Carolina at Chapel
Hill
* E-mail: jjyeh@med.unc.edu
PLoS Medicine | www.plosmedicine.org 1 July 2010 | Volume 7 | Issue 7 | e1000307Introduction
Pancreatic ductal adenocarcinoma (PDAC), comprising over
90% of all pancreatic cancers, remains a lethal disease with an
estimated 232,000 new cases, 227,000 deaths per year worldwide,
and a less than 5% 5-y survival rate [1,2]. Currently the standard
of care for the 20% of patients with localized disease is surgery
followed by chemotherapy, and in some cases radiation.
Unfortunately, despite the use of adjuvant therapy, median
survival remains at best 23 mo [3]. It is important to note,
however, that up to 27% of patients with resected PDAC can
survive for 5 y [4–10]. However, in studies examining actual
long-term survivors [4–10], only two have found that adjuvant
therapy was associated with improved survival [9,10]. In
addition, randomized controlled trials of gemcitabine-based
chemotherapy demonstrate an improvement in median survival
of at best 3 mo [3,11]. One possible conclusion from these studies
is that tumor biology dictates outcome and that our current
adjuvant therapy has only a modest impact on altering a patient’s
course.
Hypothesizing that the dismal outcome of patients with
localized disease is due to the presence of micrometastatic disease,
current clinical investigation has focused on preoperative or
neoadjuvant therapy [12,13]. This approach, in which patients
who cannot tolerate the stress of therapy or who develop
metastatic disease during treatment are spared surgery, has
demonstrated an overall survival of 34 mo in this highly selected
patient population [12,13]. Therefore the ability to select patients
who would most benefit from a neoadjuvant approach may be
important. One way to select these individuals is to define a
prognostic gene signature that can identify patients with more
aggressive tumor biology upfront.
Expression profiling of PDAC has lead to further studies of
additional molecular diagnostic and prognostic markers [14–19].
However, the search for genes of biological significance in these
large datasets continues to be challenging. One approach to
identify genes or pathways that are biologically relevant is to study
those that are of prognostic significance [20]. Lowe and colleagues
found differential gene expression changes associated with nodal
status in primary PDAC [21], suggesting that molecular
differences in primary PDAC do exist. We hypothesized that by
comparing primary PDAC tumors at the extremes of disease, we
would identify molecular changes reflective of differences in
biology within primary PDAC tumors.
Methods
Patients
PDAC samples from 15 patients with resected primary PDAC
from the University of North Carolina at Chapel Hill (UNC) and
15 patients with metastatic PDAC from the University of
Nebraska Medical Center Rapid Autopsy Pancreatic Program
(NEB) were used to derive differentially expressed genes associated
with metastatic disease. For the NEB samples, human pancreatic
tumors from decedents who had previously been diagnosed with
PDAC, and who generously consented to post mortem examina-
tions, were obtained from the institutional review board (IRB)-
approved NEB Tissue Bank. To ensure minimal degradation of
tissue, organs were harvested within 3 h post mortem and the
specimens flash frozen in liquid nitrogen.
The training cohort included 34 patients with resected PDAC
from Johns Hopkins Medical Institutions (JHMI). The testing or
validation cohort included patients from two institutions: 48 from
Northwestern Memorial Hospital (NW) and 19 from NorthShore
University HealthSystem (NSU). All samples were collected
between 1999 and 2007 at the time of operation and flash frozen
in liquid nitrogen after approval by each individual IRB. The
UNC IRB approved use of all de-identified samples for this study.
All available samples were reviewed by a single pathologist (KAV).
De-identified data including tumor, node, and metastasis (TNM),
grade or differentiation, margin status, and survival were available
for the majority of patients.
RNA Isolation and Microarray Hybridization
All RNA isolation and hybridization was performed on Agilent
(Agilent Technologies) human whole genome 4644 K DNA
microarrays and at UNC. RNA was extracted from macro-
dissected snap-frozen tumor samples using Allprep Kits (Qiagen)
and quantified using nanodrop spectrophotometry (ThermoScien-
tific). RNA quality was assessed with the use of the Bioanalyzer
2100 (Agilent Technologies). RNA was selected for hybridization
using RNA integrity number and by inspection of the 18S and 28S
ribosomal RNA. Similar RNA quality was selected across samples.
One microgram of RNA was used as a template for DNA
preparations and hybridized to Agilent 4644 K whole human
genome arrays (Agilent Technologies). cDNA was labeled with
Cy5-dUTP and a reference control (Stratagene) was labeled with
Cy3-dUTP using the Agilent (Agilent Technologies) low RNA
input linear amplification kit and hybridized overnight at 65uCt o
Agilent 4644 K whole human genome arrays (Agilent Technol-
ogies). Arrays were washed and scanned using an Agilent scanner
(Agilent Technologies). The data are publicly available in Gene
Expression Omnibus database (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE21501).
Microarray and Statistical Analysis
All array data were normalized using Lowess normalization.
Data were excluded for genes with poor spot quality or genes that
did not have mean intensity greater than 10 for one of the two
channels (green and red) in at least 70% of the experiments. The
log2 ratio of the mean red intensity over mean green intensity was
calculated for each gene and went through LOWESS normaliza-
tion [22]. Missing data were imputed using the k-nearest neighbors
imputation (KNN) with k=10 [23]. A distance weighted
discrimination (DWD) was used to detect the systematic biases
between the different datasets and then global adjustments made
to remove these biases [24]. Genes that were significantly up- or
down-regulated were identified using significance analysis of
microarrays (SAM) [25]. Two centroids were created using the
mean gene expression profile of this significant gene list from the
derivation set and used to develop a single sample predictor (SSP,
nearest centroid algorithm) [26] for an objective classifier. After
DWD, the SSP was applied to a 34-patient training set where any
new sample was compared to the resected centroid and assigned
by the SSP distance function to the resected centroid using (1 2
Pearson correlation coefficient). The X-Tile software program,
which assigns a two-population log-rank value to each sample and
then determines the best cut-point, was used to determine the best
threshold for classifying samples into high- and low-risk categories
[27]. X-Tile predicted that the (12 Pearson correlation coefficient)
distance of 1 would be the appropriate cut-point to stratify patients
into a high- and low-risk group (p=0.006). A second independent
validation cohort was then used as a test set using this
predetermined cut-point to evaluate outcome.
Survival analysis was performed using the statistical software
programs R, the R-package ‘‘survival,’’ and SPSS (SPSS, Inc.).
Overall survival (OS) was analyzed using the Kaplan-Meier
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measured by the log-rank test. The Fisher exact test was used to
analyze associations between two variables, the Pearson Chi-
square test was used to analyze association between more than two
variables. Multivariable analysis and analysis of continuous and
ordinal variables was performed using the Cox proportional
hazards regression method.
Tissue Microarrays
Tissue microarrays (TMAs; UNC2) were prepared from
formalin-fixed paraffin-embedded tissue sections using a 2-mm
punch. The arrays contained triplicate cores of matched normal
and tumor tissue as well as chronic pancreatitis when available,
from each patient. We prepared 5-mm sections from each TMA
block. Hematoxylin and eosin stained slides from each TMA block
were reviewed by a pathologist (KAV) to ensure that tissues were
cored accurately.
Immunohistochemistry
Slides with 5-mM sections from the paraffin-embedded speci-
mens were deparaffinized and rehydrated. The slides were then
subjected to alkaline heat antigen-retrieval using 1% Tris EDTA
for 20 min in a steamer. All slides were incubated with 3% H2O2
for 5 min and washed with TBS. The slides were further treated
with protein block solution (bovine serum albumin) for 20 min.
The sections were incubated with primary KLF6 1:150 antibody
(sc-7158, Santa Cruz Biotechnology) for 60 min at room
temperature. Following a TBS wash, the slides were incubated
with secondary labeled Polymer-HRP anti-rabbit (Dako K4002)
for 30 min. This was followed by a 5-min incubation with the
substrate-chromogen, 3,39-diaminobenzidine (Vector SK-4100).
The sections were counterstained with Harris hematoxylin.
Positive KLF6 staining was defined as when more than 5% of
cells expressed the marker and graded from 0 (no staining) to 4
(strong staining). The results of each protein marker were then
expressed as intensity (I) and proportion (P) of positive epithelial
cells and the score as the product of I and P [28,29]. All stained
slides were reviewed in a blinded fashion (JMA).
Results
Patient and Tumor Characteristics
In order to study the extremes of PDAC tumor biology, we
collected a diverse set of resected PDAC specimens from patients
with and without metastases. As the tumor microenvironment
is increasingly recognized to play a critical role in tumorigenesis
[30–33], tissues were macrodissected in order to preserve the
normal adjacent tissue and stroma of the tumors. The character-
istics of the dataset used to derive the signature (derivation set)
comprised 15 primary resected PDAC tumors (UNC1) and 15
primary tumors from patients with metastatic PDAC (NEB). The
training set comprised 34 patients with primary PDAC and the
independent validation test set comprised 67 patients with primary
PDAC (Tables 1 and 2). There were no differences in RNA quality
between the decedent and resected PDAC samples. Available
treatment data of the patients in the training and test sets are also
shown. One of 15 (7%) UNC1 patients received preoperative or
neoadjuvant chemotherapy and 11/15 (73%) NEB patients
received chemotherapy less than 6 mo prior to death. No patient
in the 34-patient training set received neoadjuvant chemotherapy.
Only 3% (2/67) of patients in the test set received neoadjuvant
chemotherapy and 45% (30/67) of patients received postoperative
or adjuvant chemotherapy.
Gene Expression Differences in Nonmetastatic And
Metastatic Primary Tumors
We hypothesized that we could enrich for molecular differences
in primary PDAC, which may be clinically and biologically
relevant, through examining primary tumors representing opposite
spectrums of PDAC: early (localized) and late (metastatic) stage.
To accomplish this, we compared nonmetastatic (UNC1) with
metastatic (NEB) primary PDAC tumors. As the methods of
procurement for these tumors differed, we used DWD to identify
systematic biases between the two datasets [24]. This method has
been used previously to successfully combine three breast cancer
datasets across three microarray platforms [26], across species
[34], and across multiple datasets [35,36]. We therefore used
DWD to adjust for the systematic biases between the UNC1 and
NEB datasets by taking advantage of the fact that each dataset also
had 15 normal pancreas samples assayed. In short, we used DWD
to adjust these 15 tumor-normal pairs from both datasets to have
similar distributions in principal component (PC) 16PC 2 space.
After the DWD adjustment, we used SAM to identify differentially
expressed genes [22,25]. Using a false discovery rate of 5%, we
Table 1. Patient, tumor, and treatment characteristics in the
derivation set.
Demographics (Derivation Set) NEB, n=15 UNC1, n=15
Median follow-up (mo) NA 6 (1–35)
T stage
1N A —
2 NA 2 (13%)
3 NA 12 (80%)
4 NA 1 (7%)
N stage
0 NA 7 (47%)
1 NA 8 (53%)
M stage
0 0 15 (100%)
11 5 0
Grade
1 NA 2 (14%)
2 NA 8 (57%)
3 NA 4 (29%)
Margin
Negative NA 12 (80%)
Positive NA 3 (20%)
Neoadjuvant therapy
No NA 14 (93%)
Yes NA 1 (7%)
Adjuvant therapy
No NA 11 (73%)
Yes NA 4 (27%)
Chemotherapy
No 3 (20%) NA
Yes 12 (80%) NA
Median survival (mo) NA 9 (1–35)
NA, not available.
doi:10.1371/journal.pmed.1000307.t001
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nonmetastatic and metastatic primary tumors: FBJ murine
osteosarcoma viral oncogene homolog B (Fos B), Kruppel-like
factor 6 (KLF6), nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, zeta (NFKBIZ, IKBZ, MAIL), ATPase
H+/K+ exchanging, alpha polypeptide (ATP4A), germ cell
associated 1 (GSG1), and sialic acid binding Ig-like lectin 11
(SIGLEC11) (Figure 1A; Table S1).
Development of a Classifier Using the Six-Gene Signature
We examined the relationship of our six-gene signature to
outcome using a training set of 34 patients with localized and
resected PDAC. After identifying and adjusting for systematic bias
using DWD [24], a resected centroid-based predictor [26] was
created using the 30 samples in the derivation dataset. The
centroid was then applied to the DWD-adjusted training set of
primary PDAC patients to determine the performance of the six-
gene signature. X-tile [27] was used to determine the optimal
distance function to the centroid cut-point for classifying this
training set of patients into high-risk and low-risk groups on the
basis of survival (Figure 1B and 1D). The optimal cut-point
occurred at a Pearson correlation coefficient of zero (p=0.006)
with patients with Pearson correlation coefficients greater than
zero in the low-risk and less than zero in the high-risk groups.
Application of the Six-Gene Signature to an Independent
Validation Cohort of 67 Patients
In order to evaluate the performance of the cut-point
determined by X-tile [27], we applied the cut-point to an
independent validation test set of 67 patients with primary PDAC.
Our predetermined Pearson correlation coefficient cut-point of
zero distance to the centroid successfully stratified patients into
high- (n=42) and low-risk groups (n=25) with a median overall
survival (OS) of 15 versus 49 mo (p=0.001) (Figure 1C and 1E).
Patients in the high-risk group had 1-, 2-, and 3-y estimated
survival rates of 55%, 34%, and 21%, compared to 91%, 64%,
and 56% in the low-risk group.
Previous studies in PDAC have found that nodal status is the
most predictive of outcome for patients with localized PDAC [37].
We compared our prognostic signature to current clinical
prognostic benchmarks. We found that tumors that were node
positive (p=0.091) and grade 2 or 3 trended towards a shorter
survival (p=0.080). Neither T stage (p=0.977) nor margin status
(p=0.223) were prognostic in this cohort. Treatment with
adjuvant chemotherapy (p=0.699) or with neoadjuvant chemo-
therapy (p=0.409) was also not prognostic, although only two
patients received neoadjuvant chemotherapy. We found no gene
expression changes between the tumors of the two patients who
received neoadjuvant chemotherapy and the tumors of patients
who received no treatment prior to surgery.
An important feature of any prognostic signature is that it
should be independent or additive to currently used clinicopath-
ologic prognostic criteria. We therefore compared the prognostic
importance of our molecular signature in the setting of grade
(p=0.417), nodal status (p=0.381), T stage (p=0.675), and margin
status (p=0.295). We found that our six-gene signature was the
only independent predictor of survival in the 57 patients with
complete data, with a hazard ratio of 4.1 (95% confidence interval
1.7–10.0) (Table 3).
We also looked at whether our six-gene signature was
confounded by available clinicopathological variables. We found
no association between our molecular signature, and tumor size,
grade, margin status, nodal status, and neoadjuvant or adjuvant
chemotherapy in our independent test set (Table 4).
KLF6 Expression in Primary PDAC
In order to further validate the six-gene signature, we performed
immunohistochemical analyses for KLF6, which showed a wide
range of expression values between nonmetastatic versus meta-
static samples (Figure 1A). To evaluate KLF6 protein expression,
we obtained another independent dataset of 50 patients repre-
sented on a TMA with matched normal, chronic pancreatitis, and
PDAC (UNC2, Table 2). First, using the median score of 1.5 as the
cutoff, we found that KLF6 expression was much higher in tumors
compared to normal pancreas (p,0.001) (Figure 2A and 2C).
KLF6 expression was strong in normal islet cells in agreement with
a previous study (Figure 2Ci, white arrowhead) [38]. Second, we
found that KLF6 expression with a score greater than 1.5 (high)
was associated with a shorter median survival of 11 mo compared
to 24 mo for patients with KLF6 expression scores less than 1.5
(low) (p=0.04) (Figure 2B).
Discussion
We profiled and compared nonmetastatic and metastatic
primary PDAC tumors and identified a six-gene signature.
Table 2. Patient, tumor, and treatment characteristics in the
training and testing sets.
Demographics
JHMI (Training
Set), n=34
NW/NSU
(Testing Set),
n=67
UNC2
(TMA),
n=50
Median follow-up (mo) 14 (2–54) 17 (2–59) 11 (0–51)
T stage
1 — 2 (3%) 5 (10%)
2 6 (18%) 10 (16%) 8 (16%)
3 27 (79%) 51 (81%) 32 (66%)
4 1 (3%) — 4 (8%)
N stage
0 2 (6%) 25 (38%) 15 (31%)
1 32 (94%) 41 (62%) 34 (69%)
M stage
0 34 (100%) 67 (100%) 47 (96%)
1 0 0 2 (6%)
Grade
1 1 (3%) 2 (3%) 2 (4%)
2 13 (38%) 34 (54%) 26 (54%)
3 20 (59%) 27 (43%) 20 (42%)
Margin
Negative NA 51 (80%) 7 (78%)
Positive NA 13 (20%) 2 (12%)
Neoadjuvant therapy
No 34 (100%) 65 (97%) 7 (88%)
Yes 0 2 (3%) 1 (12%)
Adjuvant therapy
No NA 30 (45%) NA
Yes NA 37 (55%) NA
Median survival (mo) 13 (2–54) 21 (3–59) 12 (0–51)
NA, not available.
doi:10.1371/journal.pmed.1000307.t002
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PLoS Medicine | www.plosmedicine.org 4 July 2010 | Volume 7 | Issue 7 | e1000307Figure 1. Identification, development, and application of a six-gene signature for PDAC. Clustering of (A) the six genes defined by SAM
evaluation of the metastatic compared to nonmetastatic primary PDAC using a false discovery rate of 5%; (B) patient samples into high- and low-risk
groups in a training set of 34 patients with localized and resected PDAC using the X-tile determined cut-point of a Pearson correlation coefficient of
zero; (C) patient samples into high- and low-risk groups in an independent test set of 67 patients with localized and resected PDAC using the
predetermined cut-point of zero. Kaplan-Meier overall survival of (D) the training set classified into high- and low-risk groups according to the X-tile
determined cut-point of a Pearson correlation coefficient of zero; (E) and the independent test set classified into high- and low-risk groups according
to the same predetermined cut-point.
doi:10.1371/journal.pmed.1000307.g001
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we show that it was prognostic in a true test set of resectable
PDAC patients. Importantly, our six-gene signature was indepen-
dently predictive of survival, stratifying patients with median
survivals of 15 compared to 49 mo, outperforming current
pathological staging criteria, suggesting that our signature will be
a powerful prognostic tool for patients with localized PDAC.
PDAC continues to be a devastating disease with few long-term
survivors. Surgery remains the standard therapy for patients
diagnosed with resectable PDAC [39]. Yet with a median survival
only of less than 2 y after surgery, the attendant postoperative
mortality rate of 2%–6% [40,41], and postoperative complication
and hospital readmission rates of 59% [41,42], the decision for
surgery should be made cautiously. Therefore, improved patient
selection for therapy is necessary. For the majority of patients who
cannot undergo surgery, gemcitabine chemotherapy remains the
best option, yet only 5%–10% of patients respond to the treatment
[43,44]. Given the current therapeutic limitations, additional
prognostic tools are needed to help a patient decide whether to
have surgery, and/or neoadjuvant chemotherapy, or when to
consider participation in a clinical trial.
Our analysis identified a surprisingly small number of genes with
differential expression between early compared to late stage primary
PDAC (Table S1). This finding suggests that primary PDAC may be
largely homogenous from a global gene expression standpoint.
Nonetheless, the differences that we identified appear to be clinically
and therefore biologically important. Our findings of molecular
differences in resected primary PDAC tumors suggest that there is
subtle biological variation in these tumors that influences outcome.
A review of previous published studies did not identify differential
expression of our six genes [15,21,45–56]. This finding is not
surprising, as previous studies examined differential gene expression
changes between either normal pancreas or chronic pancreatitis and
PDAC [15,45–56]. Only one study has looked at gene expression
changes between PDAC of different stages [21]. Ours was the first,
to our knowledge, to study molecular differences between
nonmetastatic versus metastatic primary tumors and identify and
validate a prognostic signature for PDAC.
Of the six genes identified in this study, most do not have an
obvious role in carcinogenesis. Three of the six genes demon-
strated significantly higher expression in the poor prognostic
groups (SIGLEC11, KLF6, NFKBIZ; Table S2). ATP4A, GSG1, and
SIGLEC-11 have not been studied in cancer. SIGLEC-11 is
thought to be expressed by tissue macrophages and also the brain
microglia [57]. Interestingly, a missense mutation of SIGLEC-11
(S465A) was identified in the mutation discovery screen of the
recent genome-wide sequencing of PDAC [58]. NFKBIZ, also
called IkappaB zeta, binds to the p50 subunit of nuclear factor
(NF)-kappaB and is important for interleukin-6 (IL-6) induction
and may be induced by IL-1 receptor and Toll-like receptors [57].
Given the prevalence of chronic pancreatitis and high degree of
stromal fibrosis, it is possible that NFKBIZ may play a role in
PDAC and inflammation.
KLF6 is a transcription factor and its full length transcript is
thought to be a tumor suppressor gene involved in prostate, lung,
and ovarian carcinogenesis [59]. However a splice variant KLF6-
SV1 has been shown to have oncogenic properties. The
oligonucleotide probes used in the Agilent whole human genome
array and the antibody against KLF6 did not differentiate between
the full-length and splice variant. In agreement with a previous
study [38], we found that KLF6 protein expression was higher in
tumors than normal pancreas. In addition we found that higher
KLF6 expression was associated with worse survival. Hartel et al.
further investigated KLF6-SV1 expression in their study using
real-time PCR and demonstrated that the higher KLF6 expression
seen in tissues was associated with a higher ratio of KLF6-SV1
compared to full-length KLF6. Therefore our findings that KLF6
expression is higher in tumors and is prognostic is likely in
agreement with this study.
Only one patient in the UNC1 cohort was treated with
neoadjuvant chemotherapy compared to 80% of NEB patients
who were treated with palliative chemotherapy. Although there is
a possibility that our signature may be reflective of gemcitabine
treatment or perhaps resistance, as NEB patients died of metastatic
disease despite gemcitabine treatment, the successful application of
our six-gene signature on an independent test set of patients where
only 3% of patients with localized PDAC were treated with
neoadjuvant therapy suggests that it is a rigorous predictor of
prognosis in previously untreated patients. We found no
association between our six-gene signature and whether a patient
Table 3. Cox proportional hazards regression analysis of the
six-gene signature.
Variable Hazard Ratio CI p-Value
Six-gene signature 4.1 1.7–10.0 0.002
T stage — — 0.675
N stage — — 0.381
Grade — — 0.417
Margin status — — 0.295
CI, confidence interval.
doi:10.1371/journal.pmed.1000307.t003
Table 4. Relationship between the six-gene signature and
clinicopathological variables.
Variable Six-Gene Signature
High Risk Low Risk p-Value
T stage
1 1 (50%) 1 (50%) 0.886
2 6 (60%) 4 (40%) —
3 33 (65%) 18 (35%) —
N stage
0 13 (52%) 12 (48%) 0.203
1 28 (68%) 13 (32%) —
Grade
1 1 (50%) 1 (50%) 0.788
2 22 (65%) 12 (35%) —
3 19 (70%) 8 (30%) —
Margin
Negative 31 (59%) 22 (41%) 0.344
Positive 9 (75%) 3 (25%) —
Neoadjuvant therapy
No 42 (65%) 23 (35%) 0.136
Yes 0 (0%) 2 (100%) —
Adjuvant therapy
No 24 (65%) 13 (35%) 0.801
Yes 18 (60%) 12 (40%) —
doi:10.1371/journal.pmed.1000307.t004
Prognostic Signature for Pancreatic Cancer
PLoS Medicine | www.plosmedicine.org 6 July 2010 | Volume 7 | Issue 7 | e1000307received adjuvant chemotherapy. In addition, chemotherapy
treatment in this cohort, either pre- or postoperative, did not
demonstrate a survival advantage.
Another concern is the validity of our hypothesis that gene
expression changes at different stages of primary PDAC
development may occur and be important for prognosis. Our
study is in agreement with Lowe and colleagues’ findings that
differential gene expression changes can be identified within
primary PDAC [21]. However, they did not address the
prognostic value of their findings. Several studies have also
Figure 2. Significance of KLF6 and Fos B expression in primary PDAC. (A) KLF6 staining is significantly higher in PDAC compared to normal
adjacent pancreas in an independent dataset of a 50-patient TMA (UNC2) as well as NEB samples used for the original analysis. (B) Kaplan-Meier
overall survival of 50 patients classified by high and low KLF6 scores, using the median cutoff score of 1.5. (C) KLF6 immunostaining in the primary
tumor of a patient who died of metastatic disease (ii) and in a resected primary tumor (iv). Minimal staining is seen in the matched normal adjacent
tissue of both patients (i, iii). KLF6 immunostaining in islet cells (i, white arrowhead). Arrows illustrate normal ductal epithelium. Black arrowheads
illustrate tumor.
doi:10.1371/journal.pmed.1000307.g002
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in primary tumors. In a study of molecular differences between
primary tumors and metastases, Golub and colleagues identified a
gene expression signature of metastasis present that could be
identified in primary tumors [60]. In addition, studies in
melanoma have suggested that metastatic cells may be found in
the parent primary tumor [61]. Finally studies in breast cancer
have demonstrated that gene expression changes found in breast
cancer cells with metastatic potential may be prognostic and
predictive of patients who will develop metastasis [62–64]. Our
study is the first to demonstrate that molecular differences in
metastatic PDAC can be identified at earlier stages, and that these
differences are predictive of future behavior. Whether these
molecular changes are biologically associated with metastatic
potential will require further investigation.
We have applied our six-gene signature to an independent
dataset of 67 patients, and have validated its prognostic value. In
addition, we have validated the protein expression of KLF6 in a
50-patient TMA. Although not nearly as powerful a predictor of
prognosis as our six-gene signature, we found that KLF6
expression was prognostic in our 50-patient TMA. Further
validation studies will be needed to see if KLF6 alone may be a
useful prognostic marker as others have shown [38]. Our findings
suggest that the prognostic value of KLF6 is strengthened in
evaluating the six genes in their entirety.
Studies of patients with resectable PDAC demonstrate median
survivals of up to 22 mo, equivalent to the median survival of
patients in our training and testing cohorts [3,11,65]. Our finding
that our six-gene signature is able to stratify patients, with startling
differences in survival, suggests that it may be used to select
patients for therapies. For example, for patients who are at high
operative risk, knowledge of a median survival of 49 compared to
15 mo, may be helpful in the operative decision-making process.
Similarly, patients who have a poor prognosis based on the six-
gene signature may be considered for neoadjuvant therapy.
Currently, the minority of centers use neoadjuvant therapy as a
standard of care, most instead reserve this for patients with locally
advanced unresectable or borderline resectable tumors. Therefore
the current decision-making process is based on anatomical
considerations. Our prognostic signature may refine this paradigm
such that neoadjuvant therapy is offered to patients on the basis of
biological considerations, regardless of resectability, and may allow
us to further study and maximize the benefits of neoadjuvant
treatment. In addition, as new therapies are developed, it may help
to determine whether patients may require more or less aggressive
treatment. Finally, our findings that there are molecular
differences associated with late-stage primary tumors, which
translate into differences in prognosis, suggest that the six genes
in this signature should be further studied for their potential as
biomarkers, and some of these genes, or the pathways that they fall
into, may represent new therapeutic targets.
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Background. Pancreatic cancer kills nearly a quarter of a
million people every year. It begins when a cell in the
pancreas (an organ lying behind the stomach that produces
digestive enzymes and hormones such as insulin, which
controls blood sugar levels) acquires genetic changes that
allow it to grow uncontrollably and to spread around the
body (metastasize). Nearly all pancreatic cancers are
‘‘pancreatic ductal adenocarcinomas’’ (PDACs)—tumors
that start in the cells that line the tubes in the pancreas
that take digestive juices to the gut. Because PDAC rarely
causes any symptoms early in its development, it has already
metastasized in about half of patients before it is diagnosed.
Consequently, the average survival time after a diagnosis of
PDAC is only 5–8 months. At present, the only chance for
cure is surgical removal (resection) of the tumor, part of the
pancreas, and other nearby digestive organs. The operation
that is needed for the majority of patients—the Whipple
procedure—is only possible in the fifth of patients whose
tumor is found when it is small enough to be resectable but
even with postoperative chemotherapy, these patients only
live for 23 months after surgery on average, possibly because
they have micrometastases at the time of their operation.
Why Was This Study Done? Despite this poor overall
outcome, about a quarter of patients with resectable PDAC
survive for more than 5 years after surgery. Might some
patients, therefore, have a less aggressive form of PDAC
determined by the biology of the primary (original) tumor? If
this is the case, it would be useful to be able to stratify
patients according to the aggressiveness of their disease so
that patients with very aggressive disease could be given
chemotherapy before surgery (neoadjuvant therapy) to kill
any micrometastases. At present neoadjuvant therapy is
given to patients with locally advanced, unresectable
tumors. In this study, the researchers compare gene
expression patterns in primary tumor samples collected
from patients with localized PDAC and from patients with
metastatic PDAC between 1999 and 2007 to try to identify
molecular markers that distinguish between more and less
aggressive PDACs.
What Did the Researchers Do and Find? The researchers
identified a six-gene signature that was associated with
metastatic disease using a molecular biology approach
called microarray hybridization and a statistical method
called significance analysis of microarrays to analyze gene
expression patterns in primary tumor samples from 15
patients with localized PDAC and 15 patients with metastatic
disease. Next, they used a training set of tumor samples from
another 34 patients with localized and resected PDAC,
microarray hybridization, and a graphical method called X-
tile to select a combination of expression levels of the six
genes that discriminated optimally between high-risk
(aggressive) and low-risk (less aggressive) tumors on the
basis of patient survival (a ‘‘cut-point’’). When the researchers
applied this cut-point to an independent set of 67 tumor
samples from patients with localized and resected PDAC,
they found that 42 patients had high-risk tumors. These
patients had an average survival time of 15 months; 55% of
them were alive a year after surgery. The remaining 25
patients, who had low-risk tumors, had an average survival
time of 49 months and 91% of them were alive a year after
resection.
What Do These Findings Mean? These and other
findings identify a six-gene signature that can predict
outcomes in patients with localized, resectable PDAC
better than, and independently of, established clinical
markers of outcome. If the predictive ability of this
signature can be confirmed in additional patients, it could
be used to help patients make decisions about their
treatment. For example, a patient wondering whether to
risk the Whipple procedure (2%–6% of patients die during
this operation and more than 50% have serious
postoperative complications), the knowledge that their
tumor was low risk might help them decide to have the
operation. Conversely, a patient in poor health with a high-
risk tumor might decide to spare themselves the trauma of
major surgery. The six-gene signature might also help
clinicians decide which patients would benefit most from
neoadjuvant therapy. Finally, the genes in this signature, or
the biological pathways in which they participate, might
represent new therapeutic targets for the treatment of
PDAC.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000307.
N The US National Cancer Institute provides information for
patients and health professionals about all aspects of
pancreatic cancer (in English and Spanish), including a
booklet for patients
N The American Cancer Society also provides detailed
information about pancreatic cancer
N The UK National Health Service and Cancer Research UK
include information for patients on pancreatic cancer on
their Web sites
N MedlinePlus provides links to further resources on
pancreatic cancer (in English and Spanish)
N Cure Pancreatic Cancer provides information about scien-
tific and medical research related to the diagnosis,
treatment, cure, and prevention of pancreatic cancer
N Pancreatic Cancer Action Network is a US organization that
supports research, patient support, community outreach,
and advocacy for a cure for pancreatic cancer
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